The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

Roche to acquire Adheron Therapeutics for $580m.....           Bristol-Myers's Opdivo injection gets FDA approval for NSCLC treatment.....           Johnson & Johnson begins clinical trial of Ebola vaccine regimen in Sierra Leone.....           U.K. cost watchdog gives second thumbs-up in a week to Merck's Keytruda for skin cancer.....           Pfizer turns aside yet another case alleging Zoloft caused birth defects.....           Backlash rages on over Purdue's pediatric OxyContin approval.....           Advera Health Analytics: Novartis, Allergan Alzheimer's meds linked to abnormal behavior, blood pressure side effects.....           Credit Suisse analyst lifts Lilly rating on Jardiance promise.....           Sun kills lawsuit Ranbaxy filed against FDA for pulling its Nexium generic.....           Astellas signs deal with Immunomic Therapeutics for worlwide license of LAMP-vax.....           Russia approves three-times-a-week Copaxone 40 mg/ml for treatment of RRMS.....           US FDA grants breakthrough therapy designation for Lilly?s abemaciclib.....           Alnylam begins Phase I OLE trial of ALN-AT3 to treat haemophilia.....           Biogen, Sanofi, Novartis tout long-term benefits at ECTRIMS as new competition advances.....           Experts push for trials to evaluate Roche, GSK flu drugs' pandemic potential.....           Oncologists' pricing pushback mounts as docs snub costly me-too drugs.....           Big Pharma teams up to defeat drug pricing proposal in California.....           Drug-pricing woes put the hurt on pharma junk bonds.....           Sources: Sanofi tells unions a 25% gain at French production sites is needed.....           Biogen, Sanofi, Novartis tout long-term benefits at ECTRIMS as new competition advances.....           Bayer starts Phase III riociguat trial to treat PAH in children.....           Merck, Pfizer receive FDA fast track status for avelumab to treat Merkel cell carcinoma.....           Lonza, Benitec partner to develop AAV manufacturing process for ddRNAi therapeutics.....           AcelRx announces initiation of clinical study with ARX-04 in emergency room patients with moderate-to-severe acute pain.....           Boston Therapeutics completes enrollment for BTI-320 Clinical Trial.....           Skin cancer drug pembrolizumab obtains NICE approval.....           Two's company for PCSK9 meds as Praluent, Repatha both nab coverage from top PBM.....           U.K. cost gatekeeper says 'OK' to Merck's Keytruda for advanced skin cancer.....           Valeant hits back at price-hike critics amid national scrutiny.....           Sanofi offers some data that might help Aubagio as it chases market share.....           Bristol takes aim at three more hep C niches with Daklinza.....           Merck notches another win in India patent battle over diabetes bestsellers.....           Analyst: New obstacles for Perrigo's businesses could thwart Mylan's deal logic.....           GTx enrolls first patient in Phase II enobosarm trial to treat triple negative breast cancer.....           Osiris Therapeutics begins phase III trial of OTI-15-01 for treatment of diabetic foot ulcers.....           Tarix Orphan obtains FDA fast track status for TXA127 to treat DMD.....           Bristol-Myers' Daklinza sNDAs gets FDA priority review.....           Johnson Matthey acquires Pharmorphix.....           Baxalta and Momenta announce initiation of pivotal clinical trial for M923, a biosimilar version of HUMIRA.....           McGuff Pharmaceuticals announces FDA approval for Hydroxyprogesterone Caproate Injection, USP.....           AmerisourceBergen to acquire PharMEDium for $2.5bn.....           Otsuka stares down another rival with FDA approval for Alkermes' long-acting Abilify.....           Roche CEO: Big Data needs Big Pharma, and vice versa.....           Drug price hikes a tried-and-true strategy for who's who of Big Pharma.....           Investors cheer as Arena forces out CEO and cofounder.....           AmerisourceBergen snags sterile drug compounder PharMEDium in $2.5B deal.....           Protalex to start Phase Ib trial of immune thrombocytopenia drug in France.....           Bristol-Myers Squibb to pay $14m to settle charges on bribery in China.....           Raptor acquires fluoroquinolone antibiotic Quinsair from Tripex.....           Otonomy gets FDA approval to begin Phase I trial of tinnitus product candidate OTO-311.....           William Campbell, Satoshi Omura and Youyou Tu win 2015 Nobel Prize in Physiology or Medicine.....           Dako announces FDA approval of new companion diagnostic for lung cancer.....           William Campbell, Satoshi Omura and Youyou Tu win 2015 Nobel Prize in Physiology or Medicine.....           Valeant's price-hike strategy goes far beyond two high-profile increases.....           Last-minute deal on drug exclusivity wraps up TPP negotiations.....           Payers want new guidelines, more data before easing access to diabetes' CV star Jardiance.....           Early Gilenya generics now spell trouble for rival MS drugs.....           FDA marketing police most likely to slap pharma for risk-info omissions.....           Vernalis buys US rights of Moxatag from Pragma Pharmaceuticals.....           FDA accepts Sandoz's BLA for biosimilar Etanercept.....           Ultragenyx seeks marketing authorization for Ace-ER tablets in Europe.....           FDA approves treatment combination of Gilead?s Letairis with Tadalafil for PAH.....           Anthera starts Phase 3 study of Sollpura pancreatic enzyme replacement therapy.....           Theralase completes GMP manufacture of second batch of lead drug.....           Karo Bio acquires OTC products manufacturer Swereco.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
Recent meetings

6th APS International PharmSci Conference
7-9 September 2015 - Nottingham

Exploring The 6Th APS International PharmSci Conference - A Hugh Success…

An overview from Bill Dawson, APS Chair

The flagship Academy conference was a huge success, building on its previous strengths on its return to the East Midlands Conference Centre in Nottingham. The balance between academia and industry was maintained and many young pharmaceutical scientists had their first opportunity to present either poster or podium presentation which is a major strength of PharmSci.


APS Inhaled Product Development Workshop
11 & 12 June 2015 - Loughborough

The purpose of this workshop was to provide an overview of the basics and fundamentals of aerosol science and the broad spectrum of scientific disciplines involved in the process of inhaled product development. This workshop was aimed at helping scientists new to the area to understand the development area in which they work and to put their role into context. It introduced them to the ‘language’ of product development to facilitate involvement in project teams or understand customer needs.


Latest News
APS Modulating the Pharmacokinetics of Inhaled Drugs
GlaxoSmithKline, Stevenage Thursday 5th November 2015. Purpose To critically review formulation options for modulating the pharmacokinetics of inhaled drugs after deposition in the lungs and whether such approaches can enhance the effectiveness of orally inhaled drug products. The focus will be on the underpinning science and relative merits of different formulation approaches. The overall aim is to define the state of the art regarding technologies for modulating the pharmacokinetics of inhaled drugs and identify how this can be developed. The challenge At present, no licensed orally inhaled products are formulated for modified release. The key questions for the developers of such products are: (i) is it possible to modify drug disposition in the lung post-deposition? (ii) can formulation approaches influence pharmacodynamic outcomes? Opportunities The workshop will explore the shortcomings of current or future inhaled medicines which might be satisfied by formulations that modify pharmacokinetics. This includes consideration of what further investment/knowledge is required to make this approach a reality. Examples of how modulating pharmacokinetics might provide advantages include:. Enhancing lung vs systemic distribution Prolonging lung retention for locally acting drugs Increasing bioavailability of systemically acting drugs Proposed outcomes To identify the need for modulating PK, understand current approaches to achieving PK modulation and identify what the development needs are. Specific deliverables are to:. Update on current approaches in industry and academia Review the strengths/weaknesses of alternative technologies Analyse product development challenges Identify the scientific developments required to underpin PK modification strategies Explore the possibility of cooperating pre-competitively to address gaps in knowledge For more information, to view the programme and to register, please visit us online here:. .
APS Stimulating antimicrobial innovation
National Heart & Lung Institute (NHLI), London Thursday 22nd October 2015. A one day meeting focussing on recent and current innovation in antimicrobials will be held on Thursday 22nd October 2015 at the National Heart and Lung Institute, Imperial College, London organised by the APS Microbiology and Anti-infectives Focus Group. Background to the Meeting: The pipeline of new antimicrobial agents is critically stagnant with most major pharma players having limited activity in the antibiotics arena over the past three decades. This meeting aims to capture the cutting edge of the antimicrobial innovation in the UK, to understand the barriers to antibiotic discovery, examine innovation ‘hotspots’ in the UK and highlight developments in the current funding landscape for antibiotics discovery and innovation. The purpose and aims of the APSGB Microbiology and Anti-Infectives Focus Group is to provide a forum for the discussion of all aspects of microbiology and anti-infectives research and development in the pharmaceutical industry and academia, to underpin the importance of microbiology to the pharmaceutical sciences and innovation, and to provide continuing education, resources and a voice for pharmaceutical scientists in the challenging area of antimicrobials development. Meeting Format: We are delighted to announce an exciting programme of high profile speakers who are leading experts and opinion formers in the fields of antimicrobial resistance, antibiotic discovery, novel therapeutic target development and representatives of academia, the pharmaceutical industry, SMEs and the major UK funding bodies. Key Opinion Leader Contributions from Internationally-Renowned Speakers Including: The keynote lecture will be delivered by Professor Sir Anthony Coates, Professor of Medical Microbiology at St George's, University of London and Chief Scientist officer at Helperby, a spin-out of the UK’s University of London St George’s. Anthony Coates is one of the world’s foremost experts in antibiotic resistance. In addition, there will be sessions on novel therapeutic targets for anti-infective development, antibiotic discovery from natural sources, novel antibiotic discovery platforms, the SME perspective and ‘meet the funders’.. For more information, to view the programme and to register, please visit us online:. .
APS 20th Anniversary International Pharmaceutical Photostability Conference 2015
Burleigh Court, Loughborough Monday 5th - Wednesday 7th October 2015. Registration still open!. In this International Year of Light 2015, the APS is particularly pleased to be presenting this event, which will comprise a one-day workshop and a two-day conference. The course will be suitable for those who are new to the topic of pharmaceutical photostability and photostability testing and also for those who wish to brush up on the basic concepts prior to the PPS’015 conference that will follow it. The course will cover the following topics and will include opportunities to discuss the application of the concepts presented to the attendees own situations and also to network with practitioners in the field. Fundamentals of Photochemistry Kinetics and Mechanisms of Photodegradation Practical exercise to cement concepts led by experts in the field The ICH guideline on Photostability testing and sample presentation Requirements of Irradiation Chambers Measurement of Light: Radiometry, Photometry, Actinometry The impact of excipients and packaging components on photostability Photostabilisation of drugs The business of the day will conclude with a ‘brains trust’ where participants can bring issues to a panel of experts in the field. This will be followed by a drinks reception for all participants of course and conference. The course will be presented by a panel of experts in the field of photostability and photostability testing from both academia and industry including Prof Hanne Tønnesen, Dr Steve Baertschi, Dr Allen Templeton, Dr Gregory Sluggett, David Clapham and Dr Leonardo Allain.. The conference will consist of four ½ day sessions focused on specific aspects of the field with a mix of invited speakers and submitted presentations supported by a poster session. These sessions will allow an in depth consideration of each topic. In addition each day will include a breakout session facilitated by an expert leader where delegates can provide input to various topics that require discussion by the photochemistry/photostability community.. If you would like to submit an abstract for consideration, please download the abstract form here.. This event is supported by the American Association of Pharmaceutical Scientists.. To find out more and to register, please visit us online here:
Recognition for a Pharmaceutical Scientist
Gordon Muirhead, a pharmacist who is Vice President at GSK, responsible for New Product Introduction for Oral Solid Dosage Forms, was conferred with an honorary degree of Doctor of Science by De Montfort University in July in recognition of his excellent work in the field of Quality by Design of pharmaceuticals. Bill Dawson, Chair of APS and also a pharmacist, is a Pro Chancellor at De Montfort and had the pleasure of conferring the degree. In the photo Gordon is seated, Bill is far left, Professor Andy Collop, Deputy Vice Chancellor is standing, centre and Dr Simon Oldroyd, Pro Vice Chancellor and Dean of Health and Life Sciences, far right.. Bill commented “it is really good to see academic recognition for a leader in the field of QbD which has the potential to add so much value in the pharmaceutical arena. Industry has been at the forefront of this initiative at DMU and it is a strong indication of the contributions which pharmaceutical science and scientists can make to both industry and academia.”.
Follow us
Upcoming Events
MIBio 2015: Stability of biopharmaceuticals – From molecular interactions to successful products
21 October 2015
APS Stimulating antimicrobial innovation
22 October 2015
APS Board Meeting
29 - 30 October 2015
APS Modulated PK Inhaled Drug Delivery workshop
5 November 2015
APS Regulatory Workshop
24 - 25 November 2015
Job Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.